Back to discover
Drug

F8 protein, human

In clinical development
Emerging researchLate-stage development
Also known as Alphanate, Antihemophilic Factor VIII (Pooled Human Plasma), Antihemophilic factor VIII human, Factor VIII (antihaemophilic factor)+6 more

Alphanate, Antihemophilic Factor VIII (Pooled Human Plasma), Antihemophilic factor VIII human, Factor VIII (antihaemophilic factor), Factor VIII (human), Human coagulation factor VIII, Humate-P, Wilate, factor VIII, human, Antihemophilic Factor VIII (Pooled Human Plasma), Pasteurized, Monoclonal Antibody Purified.

RxNorm826070UNII839MOZ74GK
1
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Factor VIII Prophylaxis in People With Hemophilia A Without Inhibitors

Clinical trial2026-07-07Results expected Q3 2027 · ClinicalTrials.gov

A Multi-center, Prospective Study Evaluating the Rate of Inhibitor Recurrence Following Successful ITI in Patients Receiving Ongoing Once Per Weekly Factor VIII Therapy Along With Emicizumab and in Patients Who Discontinue FVIII Therapy and Are on Emicizumab for Prophylaxis

Clinical trial2024-09-20Primary completion · ClinicalTrials.gov

Whole-genome sequencing reveals host factors underlying critical COVID-19.

Research2022-03-07Nature

Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients

Clinical trial2016-03-01Completed · ClinicalTrials.gov

An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A

Clinical trial2013-12-01Completed · ClinicalTrials.gov

Optimizing Prophylaxis in Patients With Severe Haemophilia A by Tailoring the Infusions to Individual Patients' Needs Using the Calibrated Automated Thrombin Generation Test

Clinical trial2013-05-14Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
F8 protein, human
Aliases & brands
AlphanateAntihemophilic Factor VIII (Pooled Human Plasma)Antihemophilic factor VIII humanFactor VIII (antihaemophilic factor)Factor VIII (human)Human coagulation factor VIIIHumate-PWilatefactor VIII, humanAntihemophilic Factor VIII (Pooled Human Plasma), Pasteurized, Monoclonal Antibody Purified
RxNorm CUI
826070
UNII
839MOZ74GK

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2016
1
Active studies
1
Recruiting
5
Late-stage (III+)
2
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 5
Phase 32Phase 42Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multi-center, Prospective Study Evaluating the Rate of Inhibitor Recurrence Following Successful ITI in Patients Receiving Ongoing Once Per Weekly Factor VIII Therapy Along With Emicizumab and in Patients Who Discontinue FVIII Therapy and Are on Emicizumab for Prophylaxis

Unknown statusPH IVChildren's Hospital Los Angelesn=522025

Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients

CompletedPH IVChulalongkorn Universityn=162016

A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Factor VIII Prophylaxis in People With Hemophilia A Without Inhibitors

RecruitingPH IIIHoffmann-La Rochen=1262031

An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A

CompletedPH IIIBioverativ Therapeutics Inc.n=712013

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes5
COVID-191Critical Illness1Genome, Human1Host-Pathogen Interactions1Whole Genome Sequencing1
Journals, researchers & institutions
Top journals
  • Nature1
Leading researchers
  • Abecasis GR1
  • Arumugam P1
  • Baillie JK1
  • Baras A1
  • Bentley D1
  • Bretherick AD1
  • Caulfield MJ1
  • Chan G1
Leading institutions
free-text, unnormalised
  • Centre for Global Health Research1
  • Centre for Inflammation Research1
  • Centre for Tropical Medicine and Global Health1
  • Clinical Research Centre at St Vincent's University Hospital1
  • Edinburgh Clinical Research Facility1
  • Great Ormond Street Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials